PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29718721-5	2018	EXPERT OPINION: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC.	lenvatinib	16-26	mechanistic target of rapamycin kinase	Homo sapiens	181-185	
33148422-9	2021	KEY FINDINGS: Here, we revealed that overexpressed FGFR1 and its downstream AKT/mTOR and ERK signaling activation could induce lenvatinib resistance in HCC.	lenvatinib	127-137	mechanistic target of rapamycin kinase	Homo sapiens	80-84	
28952411-3	2017	Multiple agents are now available for treatment in subsequent lines.The mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus alone or with lenvatinib) are among the most effective options.	lenvatinib	152-162	mechanistic target of rapamycin kinase	Homo sapiens	72-101	
28952411-3	2017	Multiple agents are now available for treatment in subsequent lines.The mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus alone or with lenvatinib) are among the most effective options.	lenvatinib	152-162	mechanistic target of rapamycin kinase	Homo sapiens	103-107	
28107584-1	2017	The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC).	lenvatinib	19-29	mechanistic target of rapamycin kinase	Homo sapiens	128-132